UBS AM’s Tempest Therapeutics TPST Stock Holding History

UBS AM’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-19	Closed	-$107K	–	2547
2017 Q1	$107K	Buy	+19	New	+$88.5K	﹤0.01%	2292
2015 Q3	–	Sell	-3	Closed	-$237K	–	2695
2015 Q2	$237K	Buy	+3	New	+$275K	﹤0.01%	2508

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS AM's TPST Position: Q2 2017 in Review

UBS AM sold out of Tempest Therapeutics (TPST) in Q2 2017, closing a stake of 19 shares — an estimated $107K sold.

UBS AM first reported a position in TPST in Q2 2015 and held it in 2 quarters. The position peaked at $237K in Q2 2015. 54 funds tracked by Wall St. Rank hold TPST as of Q2 2017.

UBS AM reported no remaining Tempest Therapeutics position as of Q2 2017 after selling out during the quarter.
UBS AM sold 19 Tempest Therapeutics shares in Q2 2017, an estimated $107K.
UBS AM first reported a position in Tempest Therapeutics in Q2 2015 and held it in 2 quarters.
UBS AM's Tempest Therapeutics position peaked at $237K in Q2 2015.
54 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2017.

Based on UBS AM's 13F filing for Q2 2017, filed 11 Aug 2017.